Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

NCT03765775 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma
Non-small Cell Lung Cancer
Lung Neoplasm

Interventions

BIOLOGICAL: Sintilimab
DRUG: Anlotinib Hydrochloride

Sponsor

First Hospital of Shijiazhuang City